# Patient Tolerability and Efficacy of Bowel Preparation With Split Dose Picosalax vs. Split Dose PEG

> **NCT02070341** · PHASE4 · TERMINATED · sponsor: **Queen's University** · enrollment: 5 (actual)

## Conditions studied

- Bowel Preparation

## Interventions

- **DRUG:** Polyethylene Glycol
- **DRUG:** Picosalax

## Key facts

- **NCT ID:** NCT02070341
- **Lead sponsor:** Queen's University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Significant changes to protocol and study design, study stopped to further enrollment and new study designed.
- **Last updated:** 2015-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02070341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02070341, "Patient Tolerability and Efficacy of Bowel Preparation With Split Dose Picosalax vs. Split Dose PEG". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02070341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*